How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Site-directed Mutagenesis Service Market
- By Technique Type: PCR-based Mutagenesis, Oligonucleotide-Directed Mutagenesis, CRISPR-Cas9 Mediated Mutagenesis, Restriction Enzyme-Mediated Mutagenesis, Chemical Mutagenesis
- By End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Agricultural Biotechnology Firms, Diagnostic Laboratories
- By Application: Protein Engineering, Gene Function Analysis, Drug Discovery and Development, Agricultural Trait Improvement, Vaccine Development
- By Service Model: Custom Mutagenesis Services, Standardized Mutagenesis Kits, Consultation and Design Services, High-Throughput Mutagenesis Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - PCR-based Mutagenesis leads By Technique Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Site-directed Mutagenesis Service Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Technique Type 5
End-User 5
Application 5
Service Model 4
Companies profiled
Thermo Fisher Scientific
Agilent Technologies
New England Biolabs (NEB)
GenScript Biotech Corporation
Eurofins Scientific
Takara Bio Inc.
Integrated DNA Technologies (IDT)
Bio-Rad Laboratories
Q5 Site-Directed Mutagenesis Kit (NEB)
Sigma-Aldrich (Merck)
Promega Corporation
GeneCopoeia
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →New England Biolabs (NEB)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →GenScript Biotech Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Takara Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Integrated DNA Technologies (IDT)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Q5 Site-Directed Mutagenesis Kit (NEB)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sigma-Aldrich (Merck)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Promega Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GeneCopoeia
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Twist Bioscience
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sangon Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Creative Biogene
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,440M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- PCR-based Mutagenesis48.1
- Oligonucleotide-Directed Mutagenesis8.2
- CRISPR-Cas9 Mediated Mutagenesis14.7
- Restriction Enzyme-Mediated Mutagenesis11.3
- Chemical Mutagenesis17.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,597M → $2,217M · 4.2%
Europe$1,113M → $1,516M · 3.9%
Asia Pacific$1,016M → $1,657M · 6.3%
Latin America$629.3M → $917.9M · 4.8%
Middle East and Africa$484.0M → $819.4M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.482026
5.482027
5.502028
5.512029
5.532030
5.542031
5.542032
5.562033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific9.8
- Agilent Technologies16.5
- New England Biolabs (NEB)7.4
- GenScript Biotech Corporation12.7
- Eurofins Scientific15.6
- Takara Bio Inc.10.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Technique Type34.8%
End-User33.0%
Application11.9%
Service Model20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.1
- Europe21.3
- Asia Pacific23.2
- Latin America12.9
- Middle East and Africa11.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 76 | 78 | 92 | 85 | 83 | 82 | 83 |
| Agilent Technologies | 84 | 88 | 77 | 82 | 90 | 87 | 85 |
| New England Biolabs (NEB) | 81 | 79 | 81 | 65 | 76 | 84 | 78 |
| GenScript Biotech Corporation | 82 | 59 | 72 | 76 | 59 | 67 | 69 |
| Eurofins Scientific | 57 | 55 | 58 | 73 | 54 | 53 | 58 |
| Takara Bio Inc. | 71 | 54 | 60 | 48 | 49 | 53 | 56 |
| Integrated DNA Technologies (IDT) | 50 | 54 | 53 | 52 | 62 | 44 | 53 |
| Bio-Rad Laboratories | 47 | 45 | 43 | 57 | 50 | 48 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Agilent Technologies
- New England Biolabs (NEB)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Agilent Technologies | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| New England Biolabs (NEB) | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| GenScript Biotech Corporation | ✓ | − | ◐ | ◐ | − | ✓ |
| Eurofins Scientific | ◐ | − | − | ◐ | ◐ | − |
| Takara Bio Inc. | − | ◐ | ◐ | − | − | ◐ |
| Integrated DNA Technologies (IDT) | − | − | ◐ | ◐ | − | − |
| Bio-Rad Laboratories | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Agilent Technologies85
2Thermo Fisher Scientific83
3New England Biolabs (NEB)78
4GenScript Biotech Corporation69
5Eurofins Scientific58
6Takara Bio Inc.56
7Integrated DNA Technologies (IDT)53
8Bio-Rad Laboratories48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificAgilent TechnologiesNew England Biolabs (NEB)
Challenger1
Strong scale, closing on the leaders.
GenScript Biotech Corporation
Contender1
Focused players with pockets of strength.
Eurofins Scientific
Niche3
Specialists in a single segment or region.
Takara Bio Inc.Integrated DNA Technologies (IDT)Bio-Rad Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technique Type in North America, then scale across Site-directed Mutagenesis Service Market — a $214M beachhead inside a $3.72B market.
Beachhead (SOM)$214Mobtainable near-term
Serviceable (SAM)$1.32Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
PCR-based Mutagenesis
Best fit — highest urgency & budget in Technique Type.
Economic buyer78 fit
Oligonucleotide-Directed Mutagenesis
Strong fit — clear ROI and a fast path to value.
End user65 fit
CRISPR-Cas9 Mediated Mutagenesis
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technique Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End-User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Technique Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Site-directed Mutagenesis Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified26%
Evaluation14%
Closed-won7%
$8.6KCAC
$49KLTV
5.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Site-directed Mutagenesis Service Market is a durable-growth opportunity — $5.41B by 2033, compounding at 7.3%.
TAM · 2025$3.07Btoday
TAM · 2033$5.41Bforecast
CAGR7.3%2027–2033
Cumulative$37.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.41BTotal addressable market
SAM$1.96BServiceable available market
SOM$379MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.3% CAGR
Demand compounds through 2033, outpacing GDP across Technique Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technique Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.41BLarge & growingTAM by 2033 at 7.3% CAGR
$1.96BServiceable nowreachable with today’s model
$379MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.22BBear4.7% CAGR
$5.41BBase7.3% CAGR
$6.92BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End-User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Site-directed Mutagenesis Service Market — a $1.96B market by 2033. Plan: grow share from 9.8% to 17.7%.
Market size · 2033$1.96Btotal addressable
Market CAGR10.5%2027–2033
Target share17.7%from 9.8% today
Revenue ambition$348Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.8% | 17.7% | At risk |
| Revenue | $188M | $348M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.4% | 39.9% | On track |
| Customer retention | 86.5% | 96.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technique Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End-User capability
A defensible second engine — invest in End-User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technique Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End-User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $40M capacity & capability investment
- Greenlight bolt-on M&A in End-User
- Authorise North America expansion plan
- Fund R&D program for Technique Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Site-directed Mutagenesis Service Market conversation — a $2.48B market you can size, segment and defend in minutes.
Market size · 2033$2.48Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,450+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technique Type
Goal Grow share in Technique Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 2 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificAgilent TechnologiesNew England Biolabs (NEB)GenScript Biotech CorporationEurofins ScientificTakara Bio Inc.Integrated DNA Technologies (IDT)Bio-Rad Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Site-directed Mutagenesis Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Site-directed Mutagenesis Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Site-directed Mutagenesis Kit Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportSitagliptin Tablet Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportSitagliptin Phosphate Tablets Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportSitagliptin Phosphate Monohydrate Market
Market size, share, segmentation and regional forecast.
$631M market · 2025 base year
View reportSitagliptin Phosphate Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSitagliptin Phosphate API Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportSitagliptin Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSitagliptin API Market
Market size, share, segmentation and regional forecast.
$712M market · 2025 base year
View reportSisomicin Sulfate Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSirolimus Eluting Coronary Stent System Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportSirolimus Eluting Coronary Stent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSirolimus API Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.